Navigating the Direct-to-Patient Revolution

The pharmaceutical landscape is currently undergoing massive shifts in how patients access medications, driven by the rise of digital health and evolving consumer expectations. Experts Timothy Aungst, PharmD, and Ravi Patel, PharmD, MBA, MS, explore the direct-to-patient (DTP) revolution and what these emerging models mean for the future of community pharmacy.

The Shift to Care on Demand

Health care is increasingly moving toward a model where the home is the center of care. Driven by widespread smartphone adoption and a growing consumer mentality, patients now seek health care services with the same on-demand convenience they expect from shopping or transportation.

When seeking treatment, patients today have a variety of modalities beyond the traditional primary care visit, including urgent care and telehealth services. Although these options offer convenience, they often have limited diagnostic capacity for conditions requiring objective data, such as laboratory testing or vital signs. Consequently, many virtual platforms have initially focused on low-acuity or lifestyle conditions—such as hair loss, erectile dysfunction, and birth control—where diagnostic friction is minimal.

Understanding DTC vs DTP Models

The presentation clarified the distinctions between various direct models that pharmacies must navigate, including the following:

• Direct-to-consumer (DTC): These models, popularized by startup companies such as Ro and Hims & Hers, emphasize a consumer-centric mindset. They identify a lifestyle problem (eg, weight loss or anxiety) and offer a telehealth-based solution, with the patient acting as the primary buyer and decision-maker.
• DTP: This model is increasingly favored by pharmaceutical manufacturers looking to remove friction points in the patient journey. Rather than bypassing providers, DTP models focus on easing barriers such as cost, prior authorizations, and distribution logistics to ensure a branded medication reaches the patient more efficiently.
• Direct-to-employer (DTE): In these models, pharmacy services are offered directly to employers to provide medication discounts for sponsored members.

The Rise of Pharma-Led Distribution

A major disruptor in this space is the entrance of pharmaceutical companies as direct participants in the distribution pipeline. Historically, manufacturers sold to wholesalers, who then sold to pharmacies; however, new models allow manufacturers to own the patient relationship and the point of dispensing.

Programs such as LillyDirect, Nexium Direct, and Synthroid Delivers utilize partner pharmacies to create limited-distribution networks. These programs often offer transparent, direct pricing or integrated coupons to drive higher medication uptake. This shift has expanded to include high-demand categories such as glucagon-like peptide-1 weight-loss medications, with companies leveraging shortages to offer therapies through their own virtual pathways.

Strategic Considerations for Community Pharmacies

For frontline pharmacists, the proliferation of DTP models raises critical questions regarding competition and continuity of care. When patients use multiple platforms for different medications, pharmacists may face challenges maintaining a comprehensive patient profile to check for drug-drug interactions.

Rather than viewing these models solely as competition, pharmacies are encouraged to identify their own strengths. This involves deciding whether to pursue pathway ownership—managing every aspect of a patient's care—or to act as a partnership mediator who coordinates care across various platforms. By focusing on clinical expertise and care coordination, pharmacies can remain vital wellness hubs in their communities.